A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Terminated
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels
of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease.
Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.